Ris-Rez (risvutatug rezetecan) achieved a confirmed overall response rate of 61% at 8 mg/kg in a phase Ib dose-optimisation study of relapsed extensive-stage small-cell lung cancer. The data were presented at ESMO 2026 and support the 8 mg/kg dose in the ongoing global phase III EMBOLD SCLC-301 trial.
Key points
ORR 61% (11/18 patients) at 8 mg/kg, 95% CI 35.7-82.7.
Grade 3+ treatment-related adverse events in 42% of 8 mg/kg patients; interstitial lung disease observed in 2% of all patients.
Sources
Kidney cancer vein trial 71.4% recurrence-free at one year
Kidney cancer vein trial reports 71.4% of patients were recurrence-free at one year after radiation and surgery, exceeding a 55.7% historical benchmark. The result comes from a small trial.
Key points
Recurrence-free rate: 71.4% at one year after radiation and surgery.
Historical benchmark: 55.7% recurrence-free rate.
Sources
- Original post
- medicalxpress.com - Linked in the post
In-network mental health providers appointment rate 24% in five-state test
In-network mental health providers secured appointments for only 24% of answered calls in a five-state test, showing a gap between insurance directories and access to care. The result was highlighted by Ohio State and JAMA Health Forum.
Key points
Appointment rate: 24% of answered calls secured an appointment.
Scope: Data collected from a five-state test.
Sources
- Original post
- medicalxpress.com - Linked in the post
AI app near-real-time replies in 13-person test
AI app let patients ask about brain activity and get near-real-time replies in a 13-person proof-of-concept test. Patient feedback helped it recognize seizure patterns.
Key points
Proof-of-concept test involved 13 patients
Patient feedback helped it recognize seizure patterns
Sources
- Original post
- medicalxpress.com - Linked in the post